Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial

View ORCID ProfileVincent C. Marconi, View ORCID ProfileAthimalaipet V. Ramanan, View ORCID ProfileStephanie de Bono, View ORCID ProfileCynthia E. Kartman, View ORCID ProfileVenkatesh Krishnan, View ORCID ProfileRan Liao, Maria Lucia B. Piruzeli, View ORCID ProfileJason D. Goldman, View ORCID ProfileJorge Alatorre-Alexander, Rita de Cassia Pellegrini, View ORCID ProfileVicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, View ORCID ProfilePaulo Reis, Xin Zhang, View ORCID ProfileDavid H. Adams, View ORCID ProfileE. Wesley Ely on behalf of the COV-BARRIER Study Group
doi: https://doi.org/10.1101/2021.04.30.21255934
Vincent C. Marconi
1Emory University School of Medicine, Rollins School of Public Health, Emory Vaccine Center, and the Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent C. Marconi
  • For correspondence: vcmarco@emory.edu
Athimalaipet V. Ramanan
2Translational Health Sciences, University of Bristol, Bristol, UK
3Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Athimalaipet V. Ramanan
Stephanie de Bono
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephanie de Bono
Cynthia E. Kartman
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cynthia E. Kartman
Venkatesh Krishnan
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Venkatesh Krishnan
Ran Liao
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ran Liao
Maria Lucia B. Piruzeli
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason D. Goldman
4Eli Lilly and Company, Indianapolis, IN, USA
5Swedish Center for Research and Innovation, Swedish Medical Center, Providence St. Joseph Health, and Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason D. Goldman
Jorge Alatorre-Alexander
5Swedish Center for Research and Innovation, Swedish Medical Center, Providence St. Joseph Health, and Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle, WA, USA
6Instituto Nacional de Enfermedades Respiratorias, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jorge Alatorre-Alexander
Rita de Cassia Pellegrini
7Pesquisare / Santo André, Brazil and Hospital Beneficência Portuguesa de São Caetano do Sul / São Caetano do Sul, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicente Estrada
8Hospital Clinico San Carlos-IdiSSC; Universidad Complutense, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vicente Estrada
Mousumi Som
9Oklahoma State University Medicine, Internal Medicine - Houston Center, Tulsa, OK, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anabela Cardoso
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sujatro Chakladar
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brenda Crowe
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulo Reis
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paulo Reis
Xin Zhang
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Adams
4Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David H. Adams
E. Wesley Ely
10Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine at Vanderbilt University Medical Center, and the Tennessee Valley Veteran’s Affairs Geriatric Research Education Clinical Center (GRECC), Nashville, TN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E. Wesley Ely
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard of care (SOC) in hospitalised adults with COVID-19 is unknown.

Methods In this phase 3, global, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America (ClinicalTrials.gov NCT04421027). Hospitalised adults with COVID-19 receiving SOC were randomly assigned (1:1) to once-daily baricitinib 4-mg or placebo for up to 14 days. SOC included systemic corticosteroids in 79·3% of participants (dexamethasone ∼90%). The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28. All-cause mortality by days 28 and 60 were key secondary and exploratory endpoints, respectively. Efficacy and safety analyses included the intent-to-treat and safety populations, respectively.

Findings Between June 11, 2020 and January 15, 2021, 1525 participants were randomly assigned to baricitinib 4-mg (n=764) or matched placebo (n=761). Overall, 27·8% of participants receiving baricitinib vs 30·5% receiving placebo progressed (primary endpoint, odds ratio 0·85, 95% CI 0·67-1·08; p=0·18). The 28-day all-cause mortality was 8·1% (n=62) for baricitinib and 13·1% (n=100) for placebo, corresponding to a 38·2% reduction in mortality (hazard ratio [HR] 0·57, 95% CI 0·41-0·78; nominal p=0·0018). The 60-day all-cause mortality was 10·3% (n=79) for baricitinib and 15·2% (n=116) for placebo (HR 0·62, 95% CI 0·47-0·83; p=0·0050). Frequency of serious adverse events (14·7% [n=110] vs 18·0% [n=135]), serious infections (8·5% [n=64] vs 9·8% [n=74]), and venous thromboembolic events (2·7% [n=20] vs 2·5% [n=19]) was similar between baricitinib and placebo, respectively.

Interpretation While reduction of disease progression did not achieve statistical significance, treatment with baricitinib in addition to SOC (including dexamethasone) significantly reduced mortality, with a similar safety profile to SOC, in hospitalised COVID-19 participants.

Funding Eli Lilly and Company.

Evidence before this study We searched PubMed using the terms “COVID-19”, “SARS-CoV-2”, “treatment”, “baricitinib” and “JAK inhibitor” for articles in English published up to April 31, 2020, regardless of article type. We considered previous and current clinical trials of investigational medications in COVID-19, as well as previous clinical trials of the Janus kinase (JAK)1 and JAK2 inhibitor, baricitinib, before undertaking this study. At the time the COV-BARRIER study was designed, there were no approved therapies for the treatment of COVID-19. Management of COVID-19 was supportive, and limited phase 3 randomised placebo-controlled studies had been completed. Limited phase 2 and 3 data on the antimalarial hydroxychloroquine and protease inhibitor lopinavir/ritonavir were available, and trials investigating the use of the antiviral remdesivir were ongoing. Baricitinib’s mechanism of action as a JAK1 and JAK2 inhibitor was identified as a potential intervention for the treatment of COVID-19 given its known anti-cytokine properties and potential for targeting host proteins for its antiviral mechanism. Additionally, early case series evaluating the efficacy and safety of baricitinib in the hospitalised patient population supported further evaluation of baricitinib as a potential treatment option for hospitalised patients with COVID-19. While COV-BARRIER was enrolling, ACTT-2, a phase 3 study evaluating baricitinib plus remdesivir was completed showing that baricitinib added to remdesivir improved time to recovery and other outcomes.

Added value of this study This was the first phase 3 study to evaluate baricitinib in addition to the current standard of care (SOC) and included antivirals, anticoagulants, and corticosteroids. After the earliest publication of the RECOVERY study in June 2020, the treatment of hospitalised patients with COVID-19 changed with the adoption of dexamethasone as SOC. As a result of its design, COV-BARRIER became the first trial to evaluate the benefit/risk of baricitinib when added to the most current SOC (dexamethasone) in these patients. This was a randomised, double-blind, placebo-controlled trial conducted globally in regions with high COVID-19 hospitalisation rates. The reduction in the composite primary endpoint of progression to non-invasive ventilation, high flow oxygen, invasive mechanical ventilation, or death for baricitinib plus SOC (including dexamethasone) compared to placebo plus SOC did not reach statistical significance. However, in a pre-specified key secondary endpoint, treatment with baricitinib reduced 28-day all-cause mortality by 38·2% compared to placebo (HR 0·57, 95% CI 0·41-0·78; nominal p=0·0018); one additional death was prevented per 20 baricitinib-treated participants. The reduction of all-cause mortality with baricitinib was maintained by day 60 in an exploratory analysis. The frequency of serious adverse events, serious infections, and venous thromboembolic events was similar between baricitinib and placebo, respectively.

Implications of all the available evidence In this phase 3 trial, baricitinib given in addition to SOC (which predominantly included dexamethasone) did not reduce a composite endpoint of disease progression, but showed a strong effect on reducing mortality by 28 days, an effect which was maintained by 60 days. In the ACTT-2 study, baricitinib further reduced time to recovery above the background use of remdesivir. Taken together, these findings suggest that baricitinib has synergistic effects to other SOC treatment modalities including remdesivir and dexamethasone. Based on all available evidence, baricitinib is a potentially effective oral treatment option to decrease mortality in hospitalised patients with COVID-19.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form and declare: Vincent C. Marconi received research grants from CDC, Gilead Sciences, NIH, VA, and ViiV, received honoraria from Eli Lilly and Company, served as an advisory board member for Eli Lilly and Company and Novartis and participated as a study section chair for the NIH. Athimalaipet V. Ramanan received research grants from Eli Lilly and Company, served as a speaker and/or consultant for AbbVie, Eli Lilly and Company, Novartis, Pfizer, Roche, Sobi and UCB. Stephanie de Bono, Cynthia E. Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, and David H. Adams are employees and shareholders of Eli Lilly and Company. Jason D. Goldman received research support from Eli Lilly and Company, Regeneron Pharmaceuticals, and Gilead Sciences, grants from Eurofins Viracor, the Biomedical Advanced Research and Development Authority (administered by Merck), speaker fees from Gilead Sciences, Mylan Pharmaceuticals and advisory board fees from Gilead Sciences. Rita de Cassia Pellegrini has no conflicts to disclose. Jorge Alatorre-Alexander served as a speaker and scientific advisor for Astra Zeneca, Boehringer Ingelheim, BMS, Eli Lilly and Company, Foundation Medicine, Novartis, MSD, Roche and Takeda. Vicente Estrada received a research grant from Eli Lilly and Company. Mousumi Som received research grants from Eli Lilly and Company, NIAID, Novartis and served as a board member for NBOME, Osteopathic Founders Foundation and COGMED. E. Wesley Ely received research grants from CDC, NIH and VA, and served as an unpaid consultant for Eli Lilly and Company.

Clinical Trial

NCT04421027

Funding Statement

This study was funded by Eli Lilly and Company, under license from Incyte Corporation. All authors received manuscript preparation support from Eli Lilly and Company. Stephanie de Bono, Cynthia E. Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, and David H. Adams are Employees and stockholders of Eli Lilly and Company. Jason D. Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, and Mousumi Som or their institutions were paid as study investigators. Athimalaipet V. Ramanan is a paid advisor. Vincent C. Marconi and E. Wesley Ely received no funding for this research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All sites received approval from the authorized institutional review board (See 'COV-BARRIER_IRB_Report.docx'). All patients (or legally authorized representatives) provided informed consent. An independent, external data monitoring committee oversaw the study and evaluated unblinded interim data for efficacy, futility and safety analyses. An independent, blinded, clinical event committee adjudicated potential VTEs and deaths.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* A complete list of members of the COV-BARRIER Study Group is provided in the Supplementary Appendix.

  • The manuscript was updated, including with mortality outcomes by Day 60.

Data Availability

Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after the trial is completed, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 30, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial
Vincent C. Marconi, Athimalaipet V. Ramanan, Stephanie de Bono, Cynthia E. Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Jason D. Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H. Adams, E. Wesley Ely
medRxiv 2021.04.30.21255934; doi: https://doi.org/10.1101/2021.04.30.21255934
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial
Vincent C. Marconi, Athimalaipet V. Ramanan, Stephanie de Bono, Cynthia E. Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Jason D. Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H. Adams, E. Wesley Ely
medRxiv 2021.04.30.21255934; doi: https://doi.org/10.1101/2021.04.30.21255934

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (898)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8774)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1858)
  • Geriatric Medicine (178)
  • Health Economics (387)
  • Health Informatics (1288)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10550)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1750)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (963)
  • Ophthalmology (282)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1842)
  • Public and Global Health (3979)
  • Radiology and Imaging (653)
  • Rehabilitation Medicine and Physical Therapy (343)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)